← Indivior Pharmaceuticals, Inc.

Annual Trend FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $791.0m $901.0m $1.1b $1.2b $1.2b
Revenue From Interest — $18.0m $43.0m — —
Cost of Revenue ($127.0m) $159.0m $186.0m $231.0m $246.0m
Cost of sales ($127.0m) ($159.0m) ($186.0m) — —
Reconciled Cost Of Revenue — $151.0m $174.0m $231.0m $246.0m
Gross Profit $664.0m $742.0m $907.0m $957.0m $994.0m
Research and development — $72.0m $106.0m $107.0m $97.0m
Other Operating Expenses — ($8.0m) ($9.0m) $4.0m ($3.0m)
Operating Expenses — — — $925.0m —
Operating Income (Loss) $32.0m $8.0m $6.0m $32.0m $262.0m
Additional Financial Items
General and administrative — $545.0m $575.0m — —
Average Effective Tax Rate — $0 ($1) — —
Capitalized Computer Software, Amortization — — — $3.0m $0
Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss — $13.0m $15.0m — —
Depreciation Right of Use Assets — $8.0m $9.0m — —
Finance Income $4.0m $19.0m $43.0m — —
Foreign Currency Transaction Gain (Loss), before Tax — — — $2.0m ($1.0m)
Gain (Loss) Related to Litigation Settlement — — — ($195.0m) ($3.0m)
Impairment Loss Recognised In Profit Or Loss Goodwill — — $0 — —
Income (Loss) from Continuing Operations before Income Taxes, Domestic — — — $28.0m $255.0m
Other Income — $8.0m $6.0m — —
Profit Loss Before Tax — ($95.0m) $1.0m — —
Profit Loss From Operating Activities — ($85.0m) ($4.0m) — —
Operating (loss)/profit $213.0m ($85.0m) ($4.0m) — —
Profit/(loss) before taxation $190.0m ($95.0m) $1.0m — —
Income tax benefit $15.0m $42.0m $1.0m — —
Diluted EPS — ($0.38) $0.01 ($0.36) $1.64
Diluted NI Availto Com Stockholders — ($44.0m) ($126.0m) $7.0m $210.0m
Interest Income — $19.0m $43.0m $23.0m $22.0m
Interest Income Non Operating — $19.0m $43.0m $23.0m $22.0m
Net Income From Continuing And Discontinued Operation — ($44.0m) ($126.0m) $7.0m $210.0m
Net Income From Continuing Operation Net Minority Interest — ($44.0m) ($126.0m) $7.0m $210.0m
Net Interest Income — ($8.0m) $8.0m ($18.0m) ($23.0m)
Normalized EBITDA — $250.0m $306.0m $285.0m $307.0m
Normalized Income — $189.8m $222.5m $161.8m $212.6m
Other Gand A — $251.0m $329.0m $357.0m $319.0m
Other Special Charges — $296.0m $401.0m $196.0m $3.0m
Otherunder Preferred Stock Dividend $0 $0 $0 $0 —
Reconciled Depreciation — $16.0m $15.0m $28.0m $20.0m
Restructuring And Mergern Acquisition — $0 $162.0m $1.0m —
Selling General And Administration — $469.0m $565.0m $612.0m $634.0m
Special Income Charges — ($296.0m) ($401.0m) ($196.0m) ($3.0m)
Tax Effect Of Unusual Items — ($62.2m) ($52.5m) ($41.2m) ($366k)
Tax Provision — ($44.0m) ($19.0m) $13.0m $29.0m
Tax Rate For Calcs — $0 $0 $0 $0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest — — — $14.0m $239.0m
Total Unusual Items — ($296.0m) ($401.0m) ($196.0m) ($3.0m)
Total Unusual Items Excluding Goodwill — ($296.0m) ($401.0m) ($196.0m) ($3.0m)
Pre-Tax Income — ($89.0m) ($145.0m) $20.0m $239.0m
Net Income Continuous Operations — ($45.0m) ($126.0m) $7.0m $210.0m
Net Income (Loss) Attributable to Parent $205.0m ($53.0m) $2.0m $2.0m $210.0m
Net Income Including Noncontrolling Interests — ($45.0m) ($126.0m) $7.0m $210.0m
Earnings Per Share, Basic $1.41 ($0.38) $0.01 $0.02 $1.68
Earnings Per Share, Diluted $1.35 ($0.38) $0.01 $0.02 $1.64
Weighted Average Number of Shares Outstanding, Basic — — — 132.0m 125.0m
Basic Average Shares — $139.0m $137.3m $132.3m $125.0m
Diluted Average Shares — $145.6m $141.8m $132.3m $128.0m
Weighted Average Number of Shares Outstanding, Diluted — — — 133.0m 128.0m
Research and development expenses ($52.0m) ($72.0m) ($106.0m) — —
Selling, General and Administrative Expense — $763.0m $811.0m $618.0m $634.0m
Selling, general and administrative expenses ($431.0m) ($763.0m) ($811.0m) — —
Current Tax Expense (Income) — $51.0m $61.0m — —
Deferred Tax Expense (Income) Recognised In Profit Or Loss — ($106.0m) ($56.0m) — —
Employee Benefits Expense — $240.0m $309.0m — —
Expense From Share-Based Payment Transactions With Employees — $16.0m $22.0m — —
Expense Relating To Variable Lease Payments Not Included In Measurement Of Lease Liabilities — $21.0m $22.0m — —
Finance Costs — $29.0m $38.0m — —
Other Finance Cost — $0 $1.0m — —
Postemployment Benefit Expense Defined Contribution Plans — $12.0m $14.0m — —
Finance expense ($27.0m) ($29.0m) ($38.0m) — —
Net finance income/(expense) ($23.0m) ($10.0m) $5.0m — —
Interest Expense (non-operating) — $27.0m $35.0m $41.0m $45.0m
Interest Expense, Debt — — — $32.0m $38.0m
Interest Expense On Lease Liabilities — $2.0m $3.0m — —
Current Income Tax Expense (Benefit) — — — $5.0m $75.0m
Income Tax Expense Continuing Operations — ($42.0m) ($1.0m) — —
General And Administrative Expense — $251.0m $329.0m $357.0m $319.0m
Interest Expense — $27.0m $35.0m $41.0m $45.0m
Net Non Operating Interest Income Expense — ($8.0m) $8.0m ($18.0m) ($23.0m)
Operating Expense — $535.0m $672.0m $723.0m $728.0m
Other Income Expense — ($296.0m) ($401.0m) — ($3.0m)
Selling And Marketing Expense — $218.0m $236.0m $255.0m $315.0m
Income Tax Expense (Benefit) — — — $11.0m $29.0m
Total Expenses — $686.0m $846.0m $954.0m $974.0m
Total Other Finance Cost ($2.0m) ($1.0m) $1.0m — —

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.